View ValuationMedicalgorithmics 향후 성장Future 기준 점검 5/6Medicalgorithmics (는) 각각 연간 88.9% 및 30.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 89.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.4% 로 예상됩니다.핵심 정보88.9%이익 성장률89.44%EPS 성장률Medical Equipment 이익 성장15.3%매출 성장률30.8%향후 자기자본이익률8.45%애널리스트 커버리지Low마지막 업데이트14 May 2026최근 향후 성장 업데이트Price Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.모든 업데이트 보기Recent updatesPrice Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.Buy Or Sell Opportunity • Apr 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to zł26.10. The fair value is estimated to be zł32.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 75% in a year. Earnings are forecast to grow by 84% in the next year.분석 기사 • Apr 17At zł28.35, Is Medicalgorithmics S.A. (WSE:MDG) Worth Looking At Closely?Medicalgorithmics S.A. ( WSE:MDG ), is not the largest company out there, but it saw a decent share price growth of 11...Buy Or Sell Opportunity • Mar 31Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to zł27.85. The fair value is estimated to be zł34.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 88% in a year. Earnings are forecast to grow by 89% in the next year.Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.공시 • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025Buy Or Sell Opportunity • Nov 06Now 22% overvaluedOver the last 90 days, the stock has fallen 5.5% to zł31.95. The fair value is estimated to be zł26.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.Buy Or Sell Opportunity • Oct 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 10% to zł34.50. The fair value is estimated to be zł27.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.분석 기사 • Oct 11A Look At The Intrinsic Value Of Medicalgorithmics S.A. (WSE:MDG)Key Insights Medicalgorithmics' estimated fair value is zł33.99 based on 2 Stage Free Cash Flow to Equity Current share...New Risk • Oct 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł354.3m (US$96.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Sep 08Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 64% to zł41.70. The fair value is estimated to be zł34.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 64%. Revenue is forecast to grow by 72% in a year. Earnings are forecast to grow by 50% in the next year.분석 기사 • Sep 08Would Medicalgorithmics (WSE:MDG) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025분석 기사 • Aug 15What Is Medicalgorithmics S.A.'s (WSE:MDG) Share Price Doing?WSE:MDG 1 Year Share Price vs Fair Value Explore Medicalgorithmics's Fair Values from the Community and select yours...Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.공시 • May 20Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025.New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Market cap is less than US$100m (zł225.1m market cap, or US$55.7m).Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).Reported Earnings • Oct 02Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł5.91m (down 39% from 2Q 2023). Net loss: zł5.32m (loss widened 328% from 2Q 2023).Reported Earnings • Jun 04First quarter 2024 earnings released: zł0.40 loss per share (vs zł0.15 profit in 1Q 2023)First quarter 2024 results: zł0.40 loss per share (down from zł0.15 profit in 1Q 2023). Revenue: zł7.02m (down 38% from 1Q 2023). Net loss: zł4.01m (down 364% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • May 18Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024.Reported Earnings • Apr 24Full year 2023 earnings released: zł0.06 loss per share (vs zł3.17 profit in FY 2022)Full year 2023 results: zł0.06 loss per share (down from zł3.17 profit in FY 2022). Revenue: zł43.1m (down 31% from FY 2022). Net loss: zł578.0k (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Jan 30+ 3 more updatesMedicalgorithmics S.A. to Report Fiscal Year 2023 Results on Apr 22, 2024Medicalgorithmics S.A. announced that they will report fiscal year 2023 results on Apr 22, 2024Reported Earnings • Dec 03Third quarter 2023 earnings released: zł0.019 loss per share (vs zł0.93 profit in 3Q 2022)Third quarter 2023 results: zł0.019 loss per share (down from zł0.93 profit in 3Q 2022). Revenue: zł9.57m (down 45% from 3Q 2022). Net loss: zł178.0k (down 104% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.90, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 12x in the Medical Equipment industry in Poland. Total returns to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł32.45, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 11x in the Medical Equipment industry in Poland. Total returns to shareholders of 52% over the past three years.분석 기사 • Sep 20Is Medicalgorithmics (WSE:MDG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to zł36.50, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 15x in the Medical Equipment industry in Poland. Total returns to shareholders of 33% over the past three years.Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł27.35, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 14x in the Medical Equipment industry in Poland. Total returns to shareholders of 5.0% over the past three years.New Risk • Jul 03New major risk - Revenue and earnings growthEarnings have declined by 62% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł231.9m market cap, or US$56.9m).분석 기사 • Jun 14These 4 Measures Indicate That Medicalgorithmics (WSE:MDG) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł21.85, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 7x in the Medical Equipment industry in Poland. Total loss to shareholders of 15% over the past three years.공시 • Jun 13Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023, at 14:00 Central European Standard Time.Reported Earnings • Jun 04First quarter 2023 earnings released: EPS: zł0.15 (vs zł11.14 loss in 1Q 2022)First quarter 2023 results: EPS: zł0.15 (up from zł11.14 loss in 1Q 2022). Revenue: zł11.3m (down 61% from 1Q 2022). Net income: zł1.52m (up zł57.0m from 1Q 2022). Profit margin: 14% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.분석 기사 • May 04Medicalgorithmics (WSE:MDG) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Medicalgorithmics S.A.'s ( WSE:MDG ) shareholders. Our analysis...공시 • Jan 26+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2023 Results on Nov 29, 2023Medicalgorithmics S.A. announced that they will report Q3, 2023 results on Nov 29, 2023Reported Earnings • Dec 02Third quarter 2022 earnings released: EPS: zł5.51 (vs zł0.31 loss in 3Q 2021)Third quarter 2022 results: EPS: zł5.51 (up from zł0.31 loss in 3Q 2021). Revenue: zł17.4m (down 43% from 3Q 2021). Net income: zł4.63m (up zł5.98m from 3Q 2021). Profit margin: 27% (up from net loss in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.공시 • Oct 05Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million.Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million on October 3, 2022. Bio Fund to also provide company with additional financing of up to $2.8 million (PLN 13.8 million) over three year period from share purchase.Reported Earnings • Sep 30Second quarter 2022 earnings released: EPS: zł1.39 (vs zł0.43 loss in 2Q 2021)Second quarter 2022 results: EPS: zł1.39 (up from zł0.43 loss in 2Q 2021). Revenue: zł35.5m (up 28% from 2Q 2021). Net income: zł6.93m (up zł8.79m from 2Q 2021). Profit margin: 20% (up from net loss in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.공시 • Aug 11Medicalgorithmics S.A. Secures FDA Approval for DeepRhytmAI TechnologyMedicalgorithmics S.A. has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI. It is a cloud-based Artificial Intelligence algorithm that classifies ECG signals. Without excessive human involvement, DeepRhytmAI is able to recognize a wide range of arrhythmia disorders for a more quick and accurate patient diagnosis. DeepRhytmAI is designed for use with the Company's devices but can be integrated with solutions of other providers, as well. Based on the Company's data, once DeepRhytmAI is integrated with the next generation of PocketECG system (under development) it could cut down the work needed to classify ECG signal by about 50%. DeepRhytmAI will be accessible to business partners who use its devices together with the next generation PocketECG system not earlier than in the second half of 2023. Medicalgorithmics operates in the industry of advanced telemetry for medicine. The Group provides solutions for cardiac diagnostics, especially in the area of ECG signal analysis. Its services are available in several countries and continents of the world, including North America, Asia, Europe and Australia.공시 • Jun 07Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022, at 09:00 Central European Standard Time.분석 기사 • Mar 09Is Medicalgorithmics (WSE:MDG) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Feb 01+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2022 Results on Nov 29, 2022Medicalgorithmics S.A. announced that they will report Q3, 2022 results on Nov 29, 2022공시 • Jan 22Rafal Brzoska Withdrawn from Negotiations with MedicalgorithmicsMedicalgorithmics S.A. (WSE:MDG) said on January 20, 2022 Rafal Brzoska (investor) has withdrawn from negotiations regarding purchase of company's stake. The investor said the business conditions of the deal, as well as the current economic cycle and increased variability of financial markets do not provide sufficient reasons for carrying out a potential transaction. The company continues strategic options review.Reported Earnings • Nov 17Third quarter 2021 earnings released: zł0.31 loss per share (vs zł0.80 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: zł30.6m (up 22% from 3Q 2020). Net loss: zł1.36m (loss narrowed 61% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 03Second quarter 2021 earnings released: zł0.43 loss per share (vs zł0.33 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł27.7m (up 20% from 2Q 2020). Net loss: zł1.85m (loss widened 55% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Reported Earnings • May 28First quarter 2021 earnings released: zł0.23 loss per share (vs zł0.91 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: zł31.4m (down 13% from 1Q 2020). Net loss: zł1.01m (loss narrowed 69% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 04Full year 2020 earnings released: zł3.12 loss per share (vs zł1.19 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: zł111.7m (down 36% from FY 2019). Net loss: zł12.9m (down 402% from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Feb 15New 90-day high: zł25.50The company is up 2.0% from its price of zł24.95 on 17 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 20% over the same period.공시 • Jan 29+ 3 more updatesMedicalgorithmics S.A. to Report Q1, 2021 Results on May 25, 2021Medicalgorithmics S.A. announced that they will report Q1, 2021 results on May 25, 2021Reported Earnings • Nov 26Third quarter 2020 earnings released: zł0.80 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: zł25.1m (down 41% from 3Q 2019). Net loss: zł3.44m (down zł3.52m from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 91% per year but the company’s share price has only fallen by 53% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 29New 90-day low: zł19.98The company is down 23% from its price of zł26.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 68% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: zł21.00The company is down 17% from its price of zł25.30 on 15 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 194% over the same period.이익 및 매출 성장 예측WSE:MDG - 애널리스트 향후 추정치 및 과거 재무 데이터 (PLN Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028967115212/31/2027692-49212/31/2026470-56212/31/202531-12-16-2N/A9/30/202527-15-18-5N/A6/30/202525-13-21-9N/A3/31/202524-16-19-8N/A12/31/202424-16-23-13N/A9/30/202431-12-23-12N/A6/30/202435-10-19-8N/A3/31/202439-6-20-8N/A12/31/202343-1-110N/A9/30/2023498-23-7N/A6/30/20235713112N/A3/31/20236125317N/A12/31/20226325-66N/A9/30/2022591513N/A6/30/202253-3-25-3N/A3/31/202230-4-24-9N/A12/31/202148-7-22-6N/A9/30/2021614-24-10N/A6/30/2021751-22-19N/A3/31/2021107-11-13-6N/A12/31/2020112-13-9-4N/A9/30/2020122-10-6-2N/A6/30/2020139-626N/A3/31/2020161-3-22N/A12/31/20191744513N/A9/30/201919312N/A28N/A6/30/201920014N/A36N/A3/31/201920415N/A49N/A12/31/201819914N/A44N/A9/30/201819316N/A45N/A6/30/201819522N/A47N/A3/31/201820628N/A30N/A12/31/201720326N/A29N/A9/30/201718849N/A36N/A6/30/201717845N/A33N/A3/31/201715548N/A33N/A12/31/201612840N/A35N/A9/30/201610710N/A17N/A6/30/2016798N/A9N/A3/31/2016533N/A24N/A12/31/20154914N/A17N/A9/30/20154416N/A25N/A6/30/20154017N/A21N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MDG 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(5.3%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: MDG (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: MDG 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: MDG 의 수익(연간 30.8%)이 Polish 시장(연간 4.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MDG 의 수익(연간 30.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MDG의 자본 수익률은 3년 후 8.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 03:26종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medicalgorithmics S.A.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Adrian KowollikEast Value Research GmbHLukasz KosiarskiIpopema Securities S.A.Gabriela BurdachWood & Company
Price Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.
Price Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.
Buy Or Sell Opportunity • Apr 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to zł26.10. The fair value is estimated to be zł32.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 75% in a year. Earnings are forecast to grow by 84% in the next year.
분석 기사 • Apr 17At zł28.35, Is Medicalgorithmics S.A. (WSE:MDG) Worth Looking At Closely?Medicalgorithmics S.A. ( WSE:MDG ), is not the largest company out there, but it saw a decent share price growth of 11...
Buy Or Sell Opportunity • Mar 31Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to zł27.85. The fair value is estimated to be zł34.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 88% in a year. Earnings are forecast to grow by 89% in the next year.
Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
공시 • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025
Buy Or Sell Opportunity • Nov 06Now 22% overvaluedOver the last 90 days, the stock has fallen 5.5% to zł31.95. The fair value is estimated to be zł26.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.
Buy Or Sell Opportunity • Oct 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 10% to zł34.50. The fair value is estimated to be zł27.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.
분석 기사 • Oct 11A Look At The Intrinsic Value Of Medicalgorithmics S.A. (WSE:MDG)Key Insights Medicalgorithmics' estimated fair value is zł33.99 based on 2 Stage Free Cash Flow to Equity Current share...
New Risk • Oct 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł354.3m (US$96.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.
New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Sep 08Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 64% to zł41.70. The fair value is estimated to be zł34.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 64%. Revenue is forecast to grow by 72% in a year. Earnings are forecast to grow by 50% in the next year.
분석 기사 • Sep 08Would Medicalgorithmics (WSE:MDG) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025
분석 기사 • Aug 15What Is Medicalgorithmics S.A.'s (WSE:MDG) Share Price Doing?WSE:MDG 1 Year Share Price vs Fair Value Explore Medicalgorithmics's Fair Values from the Community and select yours...
Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.
공시 • May 20Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025.
New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Market cap is less than US$100m (zł225.1m market cap, or US$55.7m).
Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).
Reported Earnings • Oct 02Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł5.91m (down 39% from 2Q 2023). Net loss: zł5.32m (loss widened 328% from 2Q 2023).
Reported Earnings • Jun 04First quarter 2024 earnings released: zł0.40 loss per share (vs zł0.15 profit in 1Q 2023)First quarter 2024 results: zł0.40 loss per share (down from zł0.15 profit in 1Q 2023). Revenue: zł7.02m (down 38% from 1Q 2023). Net loss: zł4.01m (down 364% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • May 18Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024.
Reported Earnings • Apr 24Full year 2023 earnings released: zł0.06 loss per share (vs zł3.17 profit in FY 2022)Full year 2023 results: zł0.06 loss per share (down from zł3.17 profit in FY 2022). Revenue: zł43.1m (down 31% from FY 2022). Net loss: zł578.0k (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Jan 30+ 3 more updatesMedicalgorithmics S.A. to Report Fiscal Year 2023 Results on Apr 22, 2024Medicalgorithmics S.A. announced that they will report fiscal year 2023 results on Apr 22, 2024
Reported Earnings • Dec 03Third quarter 2023 earnings released: zł0.019 loss per share (vs zł0.93 profit in 3Q 2022)Third quarter 2023 results: zł0.019 loss per share (down from zł0.93 profit in 3Q 2022). Revenue: zł9.57m (down 45% from 3Q 2022). Net loss: zł178.0k (down 104% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.90, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 12x in the Medical Equipment industry in Poland. Total returns to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł32.45, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 11x in the Medical Equipment industry in Poland. Total returns to shareholders of 52% over the past three years.
분석 기사 • Sep 20Is Medicalgorithmics (WSE:MDG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to zł36.50, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 15x in the Medical Equipment industry in Poland. Total returns to shareholders of 33% over the past three years.
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł27.35, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 14x in the Medical Equipment industry in Poland. Total returns to shareholders of 5.0% over the past three years.
New Risk • Jul 03New major risk - Revenue and earnings growthEarnings have declined by 62% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł231.9m market cap, or US$56.9m).
분석 기사 • Jun 14These 4 Measures Indicate That Medicalgorithmics (WSE:MDG) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł21.85, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 7x in the Medical Equipment industry in Poland. Total loss to shareholders of 15% over the past three years.
공시 • Jun 13Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023, at 14:00 Central European Standard Time.
Reported Earnings • Jun 04First quarter 2023 earnings released: EPS: zł0.15 (vs zł11.14 loss in 1Q 2022)First quarter 2023 results: EPS: zł0.15 (up from zł11.14 loss in 1Q 2022). Revenue: zł11.3m (down 61% from 1Q 2022). Net income: zł1.52m (up zł57.0m from 1Q 2022). Profit margin: 14% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
분석 기사 • May 04Medicalgorithmics (WSE:MDG) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Medicalgorithmics S.A.'s ( WSE:MDG ) shareholders. Our analysis...
공시 • Jan 26+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2023 Results on Nov 29, 2023Medicalgorithmics S.A. announced that they will report Q3, 2023 results on Nov 29, 2023
Reported Earnings • Dec 02Third quarter 2022 earnings released: EPS: zł5.51 (vs zł0.31 loss in 3Q 2021)Third quarter 2022 results: EPS: zł5.51 (up from zł0.31 loss in 3Q 2021). Revenue: zł17.4m (down 43% from 3Q 2021). Net income: zł4.63m (up zł5.98m from 3Q 2021). Profit margin: 27% (up from net loss in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
공시 • Oct 05Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million.Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million on October 3, 2022. Bio Fund to also provide company with additional financing of up to $2.8 million (PLN 13.8 million) over three year period from share purchase.
Reported Earnings • Sep 30Second quarter 2022 earnings released: EPS: zł1.39 (vs zł0.43 loss in 2Q 2021)Second quarter 2022 results: EPS: zł1.39 (up from zł0.43 loss in 2Q 2021). Revenue: zł35.5m (up 28% from 2Q 2021). Net income: zł6.93m (up zł8.79m from 2Q 2021). Profit margin: 20% (up from net loss in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
공시 • Aug 11Medicalgorithmics S.A. Secures FDA Approval for DeepRhytmAI TechnologyMedicalgorithmics S.A. has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI. It is a cloud-based Artificial Intelligence algorithm that classifies ECG signals. Without excessive human involvement, DeepRhytmAI is able to recognize a wide range of arrhythmia disorders for a more quick and accurate patient diagnosis. DeepRhytmAI is designed for use with the Company's devices but can be integrated with solutions of other providers, as well. Based on the Company's data, once DeepRhytmAI is integrated with the next generation of PocketECG system (under development) it could cut down the work needed to classify ECG signal by about 50%. DeepRhytmAI will be accessible to business partners who use its devices together with the next generation PocketECG system not earlier than in the second half of 2023. Medicalgorithmics operates in the industry of advanced telemetry for medicine. The Group provides solutions for cardiac diagnostics, especially in the area of ECG signal analysis. Its services are available in several countries and continents of the world, including North America, Asia, Europe and Australia.
공시 • Jun 07Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022, at 09:00 Central European Standard Time.
분석 기사 • Mar 09Is Medicalgorithmics (WSE:MDG) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Feb 01+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2022 Results on Nov 29, 2022Medicalgorithmics S.A. announced that they will report Q3, 2022 results on Nov 29, 2022
공시 • Jan 22Rafal Brzoska Withdrawn from Negotiations with MedicalgorithmicsMedicalgorithmics S.A. (WSE:MDG) said on January 20, 2022 Rafal Brzoska (investor) has withdrawn from negotiations regarding purchase of company's stake. The investor said the business conditions of the deal, as well as the current economic cycle and increased variability of financial markets do not provide sufficient reasons for carrying out a potential transaction. The company continues strategic options review.
Reported Earnings • Nov 17Third quarter 2021 earnings released: zł0.31 loss per share (vs zł0.80 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: zł30.6m (up 22% from 3Q 2020). Net loss: zł1.36m (loss narrowed 61% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 03Second quarter 2021 earnings released: zł0.43 loss per share (vs zł0.33 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł27.7m (up 20% from 2Q 2020). Net loss: zł1.85m (loss widened 55% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 28First quarter 2021 earnings released: zł0.23 loss per share (vs zł0.91 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: zł31.4m (down 13% from 1Q 2020). Net loss: zł1.01m (loss narrowed 69% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 04Full year 2020 earnings released: zł3.12 loss per share (vs zł1.19 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: zł111.7m (down 36% from FY 2019). Net loss: zł12.9m (down 402% from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Feb 15New 90-day high: zł25.50The company is up 2.0% from its price of zł24.95 on 17 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 20% over the same period.
공시 • Jan 29+ 3 more updatesMedicalgorithmics S.A. to Report Q1, 2021 Results on May 25, 2021Medicalgorithmics S.A. announced that they will report Q1, 2021 results on May 25, 2021
Reported Earnings • Nov 26Third quarter 2020 earnings released: zł0.80 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: zł25.1m (down 41% from 3Q 2019). Net loss: zł3.44m (down zł3.52m from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 91% per year but the company’s share price has only fallen by 53% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 29New 90-day low: zł19.98The company is down 23% from its price of zł26.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 68% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: zł21.00The company is down 17% from its price of zł25.30 on 15 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 194% over the same period.